Table 1 Patients’ characteristics and distribution of lymphoma categories in the two treatment cohorts
|  | MTX (n = 62) | Teniposide (n = 34) | P value |
|---|---|---|---|
Age (year) | 0.655 | ||
  < 60 | 41 (66.1%) | 24 (70.6%) |  |
  ≥ 60 | 21 (33.9%) | 10 (29.4%) |  |
Sex | 0.688 | ||
 Male | 32 (51.6%) | 19 (55.9%) |  |
 Female | 30 (48.4%) | 15 (44.1%) |  |
ECOG performance status | 0.657 | ||
 0–1 | 33 (54.1%) | 20 (58.8%) |  |
 2–4 | 28 (45.9%) | 14 (41.2%) |  |
IELSG risk | 0.619 | ||
 0–1 (low) | 18 (32.1%) | 11 (33.3%) |  |
 2–3 (intermediate) | 31 (55.4%) | 20 (60.6%) |  |
 4–5 (high) | 7 (12.5%) | 2 (6.1%) |  |
LDH (U/L) | Â | Â | 0.127 |
 Normal | 49 (79%) | 31 (91.2%) |  |
 Increased | 13 (21%) | 3 (8.8%) |  |
CSF cytology | 0.815 | ||
 Negative | 61 (98.4%) | 34 (100%) |  |
 Positive | 1 (1.6%) | 0 |  |
Tissue sample obtained bya | 0.047 | ||
 Stereotactic biopsy | 18 (29.5%) | 17 (50.0%) |  |
 Surgical partial resection | 43 (70.5%) | 17 (50.0%) |  |
Lymphoma categories | Â | Â | 0.376 |
 Diffuse large B-cell lymphoma | 59 (95.2%) | 32 (96.8%) |  |
 Burkitt/Burkitt-like lymphoma | 0 | 1 (1.6%) |  |
 Small B-cell lymphoma | 1 (1.6%) | 0 |  |
 Anaplastic large-cell lymphoma | 1 (1.6%) | 0 |  |
 T lymphoblastic lymphoma | 1 (1.6%) | 0 |  |
 T-cell lymphoma, unclassified | 0 | 1 (1.6%) |  |
Comorbidities | 19 (30.6%) | 12 (35.3%) | 0.806 |
MTX/TEN combination | 0.501 | ||
 With rituximab | 23 (37.1%) | 15 (44.1%) |  |
 Without rituximab | 39 (62.9%) | 19 (55.9%) |  |
Radiotherapy | 0.161 | ||
 Yes | 25 (42.4) | 19 (57.6) |  |
 No | 34 (57.6) | 14 (42.4) |  |